Galectin Therapeutics Reports Second Quarter 2012 Financial Results
16:01 EDT 10 Aug 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of
therapeutics that target galectin proteins to treat fibrosis and cancer,
today reported its financial results for the second quarter and first
six months ended ...
Other Sources for this Article
Galectin Therapeutics
Tom McGauley, 617-559-0033
Acting Chief
Financial Officer
ir@galectintherapeutics.com
More From BioPortfolio on "Galectin Therapeutics Reports Second Quarter 2012 Financial Results"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
